A big plus for Roche today after the European Commission issued a final positive decision for its once- or twice-monthly anaemia drug Mircera for use in chronic kidney disease patients that is valid ...

Roche announced today that the European Commission has approved its innovative drug Mircera to treat anaemia associated with chronic kidney disease (CKD). The approval of Mircera results in a single ...

ZURICH (MarketWatch) -- Roche Holding AG RHHBY Thursday said its anemia drug Mircera, a follow-up to a blockbuster that's losing patent protection, received approval to be sold in the European Union ...

The approval was based on an open-label, multiple dose, multicenter, dose-finding study in 64 pediatric patients with CKD who were on hemodialysis and who had stable hemoglobin levels while previously ...

ZURICH, April 13 (Reuters) - Swiss drugmaker Roche's experimental medicine Mircera is safe and effective for the treatment of renal anaemia associated with chronic kidney disease, pooled data from ...

Researchers have successfully developed a new electrophoretic method for detecting MIRCERA and other erythropoietins (EPO) in the blood. The technique, using SARCOSYL-PAGE, has specifically enhanced ...

Please provide your email address to receive an email when new articles are posted on . It is an exciting time in the treatment of renal anemia, with several new therapies recently launched or ...

IN 2015 VIFOR PHARMA (FORMERLY A COMPANY OF GALENICA GROUP) ENTERED INTO AN EXCLUSIVE LICENSE AGREEMENT WITH ROCHE FOR THE COMMERCIALISATION OF ITS MEDICINE MIRCERA ® in the US. MIRCERA ® IS A ...

Please provide your email address to receive an email when new articles are posted on . The FDA approved Mircera for the treatment of pediatric patients 5 to 17 years of age on hemodialysis who are ...

US regulators have given the green light to Roche's new anaemia drug Mircera, but no launch across the Atlantic is likely for some time as the Swiss firm is embroiled in a legal dispute it is losing ...

Roche Pharmaceuticals quickly rejected claims that Roche planted secret molecule in Mircera which allowed for detection of the CERA class drug at the 2008 Tour de France. John Fahey, WADA president, ...